文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

膀胱小细胞癌治疗结局:英国患者回顾性队列研究

Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-06

该研究回顾性分析了英国26家机构2006至2016年间409例纯或主要组织学类型的膀胱小细胞癌(SCCB)患者,中位总生存(OS)为15.9个月,接受原发化疗者OS改善,器官局限性疾病生存优于进展期,脑转移罕见。

要点

  • 409例SCCB患者中位OS为15.9个月,73.6%已死亡。
  • 接受原发化疗者中位OS为21.6个月,未接受者为9.1个月。
  • 膀胱局限性疾病中位OS为28.3个月,优于进展期患者的12.7个月。

核心结论

  • SCCB患者总体预后差,但接受化疗和器官局限性疾病者生存改善,脑转移罕见。

研究设计与样本

  • 回顾性分析2006至2016年间英国26家机构收治的409例纯或主要组织学SCCB患者,数据截止2018年2月1日。

主要发现

  • 中位年龄71岁(范围35-96岁),306例(74.8%)为男性,189例(46.2%)为纯组织学SCCB。
  • 中位OS为15.9个月(95%CI 13.2-18.7个月),301例(73.6%)死亡。
  • 膀胱局限性疾病(N0M0)200例(48.9%)中位OS为28.3个月(95%CI 20.9-35.8个月),进展期(N1-3和/或M1)172例(42.1%)中位OS为12.7个月(95%CI 10.9-14.6个月),HR 2.03(95%CI 1.58-2.60,P<.001)。
  • 接受原发化疗247例(61.5%)中位OS为21.6个月(95%CI 15.5-27.6个月),未接受者中位OS为9.1个月(95%CI 5.4-12.8个月),HR 0.46(95%CI 0.37-0.59,P<.001)。
  • 膀胱局限性疾病中,61例(30.5%)行膀胱切除术,104例(52.0%)接受放疗,两者生存结局相似;仅6例(1.5%)出现脑转移。

临床怎么用

  • 对适合的SCCB患者应优先考虑原发化疗以改善生存。
  • 膀胱局限性疾病可选择膀胱切除术或放疗,两者生存相似。
  • 脑转移罕见,常规脑影像筛查的价值需结合个体情况评估。

局限性

  • 回顾性研究设计,存在选择偏倚和信息偏倚可能。
  • 纯组织学与主要组织学SCCB混合分析,异质性可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Small cell carcinoma of the bladder (SCCB) is rare, accounting for less than 1% of all bladder carcinomas. It is aggressive, and outcomes are poor as a result of its early metastatic spread. Owing to its rarity, there are limitations on data to propose standardized management pathways. METHODS AND MATERIALS: We conducted a retrospective analysis of patients presenting with pure or predominant-histology SCCB to 26 institutions in the United Kingdom between 2006 and 2016. The data cutoff date was February 1, 2018. We report patient characteristics, treatment received, and subsequent clinical outcomes. RESULTS: A total of 409 eligible patients were included. Among these, 306 (74.8%) were male, the median age was 71 years (range, 35-96 years), and 189 patients (46.2%) had pure-histology SCCB. At data cutoff, 301 patients (73.6%) had died. The median overall survival (OS) was 15.9 months (95% CI, 13.2-18.7 months). Two hundred patients (48.9%) were confirmed to have bladder-confined disease (N0, M0), with a median OS of 28.3 months (95% CI, 20.9-35.8 months), versus a median OS of 12.7 months (95% CI, 10.9-14.6 months) for the 172 patients (42.1%) with confirmed N1-3 and/or M1 disease (hazard ratio [HR], 2.03; 95% CI, 1.58-2.60; P < .001). A total of 247 patients (61.5%) received primary chemotherapy, with a median OS of 21.6 months (95% CI, 15.5-27.6 months), versus a median OS of 9.1 months (95% CI, 5.4-12.8 months) in patients who did not receive primary chemotherapy (HR, 0.46; 95% CI, 0.37-0.59; P < .001). Choice of chemotherapy agent did not alter outcomes. For those with bladder-confined disease, 61 (30.5%) underwent cystectomy, and 104 (52.0%) received radiation therapy. Survival outcomes were similar for both cystectomy and radiation therapy. Only 6 patients (1.5%) were identified as having brain metastases at any time point. CONCLUSIONS: To our knowledge, this is the largest retrospective study of all-stage SCCB to date. Patients have a poor prognosis overall, but survival is improved in those able to receive chemotherapy and with organ-confined disease. Brain metastases are rare.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chau C, Rimmer Frcr Y, Choudhury PhD A, et al. Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study. Int J Radiat Oncol Biol Phys. 2021. PMID: 33561506. doi:10.1016/j.ijrobp.2021.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。